[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540188":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":38,"centralContacts":42,"locations":52,"responsibleParty":337,"collaborators":33,"id":339,"slug":33,"hasResults":340,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":33,"eligibilityCriteria":344,"healthyVolunteers":340,"sex":345,"minAge":346,"maxAge":33,"enrollmentInfo":347,"targetDuration":33,"studyType":350,"phases":351,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":55,"whyStopped":33,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":367},{"fullName":5,"class":6},"Incyte Corporation","INDUSTRY",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 Dose Escalation - with MF, PV or ET","EXPERIMENTAL","INCB160058 will be administered at a protocol defined starting regimen to identify the maximum tolerated dose (MTD) and\u002For recommended dose for expansion (RDE\\[s\\]). Participants with myelofibrosis (MF), polycythemia vera (PV) or essential thrombocythemia (ET) will enroll in this group.",[13],"Drug: INCB160058",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 1 Dose Escalation - with MF SubOpt R","INCB160058 will be administered at a protocol defined starting regimen and will allow for the evaluation of INCB160058 in combination with a standard disease-directed therapy to identify the maximum tolerated dose (MTD) and\u002For recommended dose for expansion (RDE\\[s\\]). Participants with myelofibrosis (MF), suboptimal response to a standard disease-directed therapy (SubOpt R) will enroll in this group.",[13,18],"Drug: Standard disease-directed therapy",{"label":20,"type":10,"description":21,"interventionNames":22},"Part 2 Dose Expansion - with MF, PV or ET","INCB160058 will be administered at the RDE(s) identified during Part 1. Participants with MF, PV or ET will enroll in this group.",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"Part 2 Dose Expansion - with MF SubOpt R","INCB160058 will be administered as an add-on therapy in combination with a standard disease-directed therapy at the RDE(s) identified during Part 1. Participants with myelofibrosis (MF), suboptimal response to a standard disease-directed therapy (SubOpt R) will enroll in this group.",[13,18],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","INCB160058","Oral; Tablet",[15,9,24,20],null,{"type":29,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"Standard disease-directed therapy","A standard disease-directed therapy will be administered according to Prescribing Information\u002FSmPC.",[15,24],[39],{"name":40,"affiliation":5,"role":41},"Incyte Medical","STUDY_DIRECTOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":33,"email":47},"Incyte Corporation Call Center (US)","CONTACT","1.855.463.3463","medinfo@incyte.com",{"name":49,"role":45,"phone":50,"phoneExt":33,"email":51},"Incyte Corporation Call Center (ex-US)","+800 00027423","eumedinfo@incyte.com",[53,66,76,86,96,106,116,125,131,137,147,157,167,177,188,198,204,214,223,233,243,252,262,271,280,290,299,309,318,328],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":33},"The University of Alabama At Birmingham","RECRUITING","Birmingham","Alabama","35249","United States",{"type":61,"coordinates":62},"Point",[63,64],-86.80249,33.52066,{"lat":64,"lon":63},{"facility":67,"status":55,"city":68,"state":69,"zip":70,"country":59,"cosmosGeoPoint":71,"geoPoint":75,"contacts":33},"Stanford University","Palo Alto","California","94304",{"type":61,"coordinates":72},[73,74],-122.14302,37.44188,{"lat":74,"lon":73},{"facility":77,"status":55,"city":78,"state":79,"zip":80,"country":59,"cosmosGeoPoint":81,"geoPoint":85,"contacts":33},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":61,"coordinates":82},[83,84],-82.45843,27.94752,{"lat":84,"lon":83},{"facility":87,"status":55,"city":88,"state":89,"zip":90,"country":59,"cosmosGeoPoint":91,"geoPoint":95,"contacts":33},"Northwestern University","Chicago","Illinois","60611",{"type":61,"coordinates":92},[93,94],-87.65005,41.85003,{"lat":94,"lon":93},{"facility":97,"status":55,"city":98,"state":99,"zip":100,"country":59,"cosmosGeoPoint":101,"geoPoint":105,"contacts":33},"The University of Kansas Cancer Center Kucc University of Kansas Clinical Research Center","Fairway","Kansas","66205",{"type":61,"coordinates":102},[103,104],-94.6319,39.02223,{"lat":104,"lon":103},{"facility":107,"status":55,"city":108,"state":109,"zip":110,"country":59,"cosmosGeoPoint":111,"geoPoint":115,"contacts":33},"University of Michigan","Ann Arbor","Michigan","48109-5008",{"type":61,"coordinates":112},[113,114],-83.74088,42.27756,{"lat":114,"lon":113},{"facility":117,"status":55,"city":118,"state":118,"zip":119,"country":59,"cosmosGeoPoint":120,"geoPoint":124,"contacts":33},"Cornell Medical Center","New York","10021",{"type":61,"coordinates":121},[122,123],-74.00597,40.71427,{"lat":123,"lon":122},{"facility":126,"status":55,"city":118,"state":118,"zip":127,"country":59,"cosmosGeoPoint":128,"geoPoint":130,"contacts":33},"Icahn School of Medicine At Mount Sinai","10029",{"type":61,"coordinates":129},[122,123],{"lat":123,"lon":122},{"facility":132,"status":55,"city":118,"state":118,"zip":133,"country":59,"cosmosGeoPoint":134,"geoPoint":136,"contacts":33},"Sloan Kettering Institute For Cancer Research","10065",{"type":61,"coordinates":135},[122,123],{"lat":123,"lon":122},{"facility":138,"status":55,"city":139,"state":140,"zip":141,"country":59,"cosmosGeoPoint":142,"geoPoint":146,"contacts":33},"Oregon Health & Science University","Portland","Oregon","97239",{"type":61,"coordinates":143},[144,145],-122.67621,45.52345,{"lat":145,"lon":144},{"facility":148,"status":55,"city":149,"state":150,"zip":151,"country":59,"cosmosGeoPoint":152,"geoPoint":156,"contacts":33},"University of Pennsylvania Health System","Philadelphia","Pennsylvania","19104",{"type":61,"coordinates":153},[154,155],-75.16362,39.95238,{"lat":155,"lon":154},{"facility":158,"status":55,"city":159,"state":160,"zip":161,"country":59,"cosmosGeoPoint":162,"geoPoint":166,"contacts":33},"Vanderbilt-Ingram Cancer Center","Nashville","Tennessee","37232",{"type":61,"coordinates":163},[164,165],-86.78444,36.16589,{"lat":165,"lon":164},{"facility":168,"status":55,"city":169,"state":170,"zip":171,"country":59,"cosmosGeoPoint":172,"geoPoint":176,"contacts":33},"Md Anderson Cancer Center","Houston","Texas","77030",{"type":61,"coordinates":173},[174,175],-95.36327,29.76328,{"lat":175,"lon":174},{"facility":178,"status":55,"city":179,"state":180,"zip":181,"country":182,"cosmosGeoPoint":183,"geoPoint":187,"contacts":33},"Princess Margaret Cancer Center","Toronto","Ontario","M5G 2M9","Canada",{"type":61,"coordinates":184},[185,186],-79.39864,43.70643,{"lat":186,"lon":185},{"facility":189,"status":55,"city":190,"state":191,"zip":192,"country":182,"cosmosGeoPoint":193,"geoPoint":197,"contacts":33},"Hopital Maisonneuve-Rosemont, Montreal, Qc","Montreal","Quebec","H1T 2M4",{"type":61,"coordinates":194},[195,196],-73.58781,45.50884,{"lat":196,"lon":195},{"facility":199,"status":55,"city":190,"state":191,"zip":200,"country":182,"cosmosGeoPoint":201,"geoPoint":203,"contacts":33},"McGill University Jewish General Hospital","H3T 1E2",{"type":61,"coordinates":202},[195,196],{"lat":196,"lon":195},{"facility":205,"status":55,"city":206,"state":33,"zip":207,"country":208,"cosmosGeoPoint":209,"geoPoint":213,"contacts":33},"Hospital Saint Louis","Paris","75010","France",{"type":61,"coordinates":210},[211,212],2.3488,48.85341,{"lat":212,"lon":211},{"facility":215,"status":55,"city":216,"state":33,"zip":217,"country":208,"cosmosGeoPoint":218,"geoPoint":222,"contacts":33},"Institut Gustave Roussy","Villejuif","94805",{"type":61,"coordinates":219},[220,221],2.35992,48.7939,{"lat":221,"lon":220},{"facility":224,"status":55,"city":225,"state":33,"zip":226,"country":227,"cosmosGeoPoint":228,"geoPoint":232,"contacts":33},"University Medical Center Rwth Aachen","Aachen","D-52074","Germany",{"type":61,"coordinates":229},[230,231],6.08342,50.77664,{"lat":231,"lon":230},{"facility":234,"status":235,"city":236,"state":33,"zip":237,"country":227,"cosmosGeoPoint":238,"geoPoint":242,"contacts":33},"Universitatsklinikum Essen","NOT_YET_RECRUITING","Essen","45147",{"type":61,"coordinates":239},[240,241],7.01228,51.45657,{"lat":241,"lon":240},{"facility":244,"status":55,"city":245,"state":33,"zip":246,"country":227,"cosmosGeoPoint":247,"geoPoint":251,"contacts":33},"Universitatsklinikum Halle (Saale)","Halle","06120",{"type":61,"coordinates":248},[249,250],11.97947,51.48158,{"lat":250,"lon":249},{"facility":253,"status":235,"city":254,"state":33,"zip":255,"country":256,"cosmosGeoPoint":257,"geoPoint":261,"contacts":33},"Aou Policlinico S. Orsola-Malpighi","Bologna","40138","Italy",{"type":61,"coordinates":258},[259,260],11.33875,44.49381,{"lat":260,"lon":259},{"facility":263,"status":235,"city":264,"state":33,"zip":265,"country":256,"cosmosGeoPoint":266,"geoPoint":270,"contacts":33},"Azienda Ospedaliero-Universitaria Careggi (Aouc)","Florence","50134",{"type":61,"coordinates":267},[268,269],11.24626,43.77925,{"lat":269,"lon":268},{"facility":272,"status":235,"city":273,"state":33,"zip":274,"country":256,"cosmosGeoPoint":275,"geoPoint":279,"contacts":33},"Fondazione Irccs Ca Granda Ospedale Maggiore","Milan","20122",{"type":61,"coordinates":276},[277,278],9.18951,45.46427,{"lat":278,"lon":277},{"facility":281,"status":55,"city":282,"state":33,"zip":283,"country":284,"cosmosGeoPoint":285,"geoPoint":289,"contacts":33},"Haukeland University Hospital","Bergen","N-5021","Norway",{"type":61,"coordinates":286},[287,288],5.32415,60.39299,{"lat":288,"lon":287},{"facility":291,"status":55,"city":292,"state":33,"zip":293,"country":284,"cosmosGeoPoint":294,"geoPoint":298,"contacts":33},"Oslo University Hospital","Oslo","00379",{"type":61,"coordinates":295},[296,297],10.74609,59.91273,{"lat":297,"lon":296},{"facility":300,"status":55,"city":301,"state":33,"zip":302,"country":303,"cosmosGeoPoint":304,"geoPoint":308,"contacts":33},"Inselspital - Universitaetsspital Bern","Bern","03010","Switzerland",{"type":61,"coordinates":305},[306,307],7.44744,46.94809,{"lat":307,"lon":306},{"facility":310,"status":55,"city":311,"state":33,"zip":312,"country":303,"cosmosGeoPoint":313,"geoPoint":317,"contacts":33},"Universitatsspital Zurich","Zurich","08091",{"type":61,"coordinates":314},[315,316],8.55,47.36667,{"lat":316,"lon":315},{"facility":319,"status":235,"city":320,"state":33,"zip":321,"country":322,"cosmosGeoPoint":323,"geoPoint":327,"contacts":33},"Guys and St Thomas Nhs Foundation Trust","London","SE1 9RT","United Kingdom",{"type":61,"coordinates":324},[325,326],-0.12574,51.50853,{"lat":326,"lon":325},{"facility":329,"status":235,"city":330,"state":33,"zip":331,"country":322,"cosmosGeoPoint":332,"geoPoint":336,"contacts":33},"Genesiscare Oxford","Oxford","OX4 6LB",{"type":61,"coordinates":333},[334,335],-1.25596,51.75222,{"lat":335,"lon":334},{"type":338,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100540188",false,"NCT06313593","A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms","A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms","Inclusion Criteria:\n\n* Age ≥ 18 years\n* MF:\n\n  * Intermediate-1 or higher risk PMF, post-PV MF, or post-ET MF with evidence of minimum burden of disease based on splenomegaly, and for the monotherapy cohort, participants must have been previously treated with at least 1 JAK inhibitor for ≥ 12 weeks and resistant, refractory, intolerant to, or have lost response to JAK inhibitor treatment.\n  * For the MF SubOpt R cohort: Therapeutic regimen prior to enrollment as defined in the protocol and unlikely to benefit from further monotherapy in the opinion of the investigator.\n* PV: Confirmed diagnosis of PV and previously treated with at least 1 prior standard cytoreductive therapy and are resistant, refractory, intolerant to, or have lost response to treatment.\n* ET: Confirmed diagnosis of high-risk ET as defined in the protocol and previously treated with at least 1 prior standard cytoreductive therapy and are resistant, refractory, intolerant to, or have lost response to treatment.\n* Life expectancy \\> 6 months.\n* Willingness to undergo a pretreatment and regular on-study bone marrow biopsies and aspirations (as appropriate to disease).\n* Existing documentation of JAK2V617F mutation from a qualified local laboratory.\n\nExclusion Criteria:\n\n* Presence of a hematological malignancy requiring treatment, other than PMF, post-PV MF, post-ET MF, PV, or ET.\n* Prior history of major bleeding or thrombosis within the 3 months prior to study enrollment.\n* Participants with abnormal hematologic, hepatic, or renal function based on laboratory evaluation.\n* Has undergone prior allogenic or autologous stem-cell transplantation or allogenic stem-cell transplantation is planned\n* Active invasive malignancy.\n* Significant concurrent, uncontrolled medical condition.\n* Acute or chronic HBV, active HCV or known HIV.\n* Any prior MPN-directed therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.\n* Participants undergoing treatment with G-CSF or GM-CSF, romiplostim, or eltrombopag at any time within 4 weeks before the first dose of study treatment.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria may apply.","ALL","18 Years",{"count":348,"type":349},186,"ESTIMATED","INTERVENTIONAL",[352],"PHASE1","This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.",[355],"Myeloproliferative Neoplasms",[355,30,357],"Myelofibrosis","2026-04-30",{"date":360,"type":361},"2026-05-04","ACTUAL",{"date":363,"type":361},"2024-08-08",{"date":365,"type":349},"2028-10-09",{"name":5,"class":6},30]